Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The nuclear receptor hepatocyte nuclear factor 4 (HNF-4) is an important regulator of several genes involved in diverse metabolic and developmental pathways. Mutations in the HNF-4A gene are responsible for the maturity-onset diabetes of the young type 1. Recently, we showed that the 24 N-terminal residues of HNF-4 function as an acidic
transcriptional activator
, termed AF-1 (Hadzopoulou-Cladaras, M., Kistanova, E., Evagelopoulou, C., Zeng, S. , Cladaras C., and Ladias, J. A. A. (1997) J. Biol. Chem. 272, 539-550). To identify the critical residues for this activator, we performed an extensive genetic analysis using site-directed mutagenesis. We showed that the aromatic and bulky hydrophobic residues Tyr6, Tyr14, Phe19, Lys10, and Lys17 are essential for AF-1 function. To a lesser degree, five acidic residues are also important for optimal activity. Positional changes of Tyr6 and Tyr14 reduced AF-1 activity, underscoring the importance of primary structure for this activator. Our analysis also indicated that AF-1 is bipartite, consisting of two modules that synergize to activate transcription. More important, AF-1 shares common structural motifs and molecular targets with the activators of the
tumor suppressor protein p53
and NF-kappaB-p65, suggesting similar mechanisms of action. Remarkably, AF-1 interacted specifically with multiple transcriptional targets, including the TATA-binding protein; the TATA-binding protein-associated factors TAFII31 and TAFII80; transcription factor IIB; transcription factor IIH-p62; and the coactivators cAMP-responsive element-binding protein-binding protein, ADA2, and PC4. The interaction of AF-1 with proteins that regulate distinct steps of transcription may provide a mechanism for synergistic activation of gene expression by AF-1.
...
PMID:Critical structural elements and multitarget protein interactions of the transcriptional activator AF-1 of hepatocyte nuclear factor 4. 979 14
The yeast
transcriptional activator
Adr1p controls expression of the glucose-repressible alcohol dehydrogenase gene (ADH2), genes involved in glycerol metabolism, and genes required for peroxisome biogenesis and function. Previous data suggested that promoter-specific activation domains might contribute to expression of the different types of ADR1-dependent genes. By using gene fusions encoding the Gal4p DNA binding domain and portions of Adr1p, we identified a single, strong acidic activation domain spanning amino acids 420-462 of Adr1p. Both acidic and hydrophobic amino acids within this activation domain were important for its function. The critical hydrophobic residues are in a motif previously identified in
p53
and related acidic activators. A mini-Adr1 protein consisting of the DNA binding domain of Adr1p fused to this 42-residue activation domain carried out all of the known functions of wild-type ADR1. It conferred stringent glucose repression on the ADH2 locus and on UAS1-containing reporter genes. The putative inhibitory region of Adr1p encompassing the protein kinase A phosphorylation site at Ser-230 is thus not essential for glucose repression mediated by ADR1. Mini-ADR1 allowed efficient derepression of gene expression. In addition it complemented an ADR1-null allele for growth on glycerol and oleate media, indicating efficient activation of genes required for glycerol metabolism and peroxisome biogenesis. Thus, a single activation domain can activate all ADR1-dependent promoters.
...
PMID:Characterization of a p53-related activation domain in Adr1p that is sufficient for ADR1-dependent gene expression. 982 83
The growth suppressor
p53
is an important key element which controls cell cycle progression in response to cellular stress like DNA damage. Its ability to act as
transcriptional activator
or repressor links transcription and cell cycle control. Several target genes selectively transactivated by
p53
are implicated in growth control, apoptosis and DNA repair. Here we report the interaction of
p53
with another important dual player of cell cycle control and transcription, the protein kinase complex CDK7/cyclin H/Mat1 (CDK activating kinase, CAK kinase). This is implicated in the activating phosphorylation of CDK2/cyclin A kinase required to allow cells to proceed through the G1/S transition, and on the other hand, as a component of the basal transcription factor TFIIH found to be necessary for CTD phosphorylation of RNA polymerase II in order to allow elongation of transcription. Based on previous binding studies of
p53
with other C-terminal interaction partners of
p53
we demonstrate a direct physical interaction of
p53
with cyclin H in vitro and in vivo. As a consequence of this interaction we tested the influence of
p53
on the kinase activity of CAK kinase for CTD and CDK2 phosphorylation. The addition of wild type
p53
to the kinase reactions resulted in a significant downregulation of CDK2 phosphorylation and CTD phosphorylation by the CDK activating kinase. On the other hand addition of a mutant p53His175 failed to downregulate CDK2 and CTD phosphorylation by the CDK activating kinase. In an attempt to support our findings in vivo we measured CAK kinase activity in p21-/- and
p53
-/- mice embryonal fibroblasts under conditions when
p53
gets activated by irradiation. In the case of p21-/- cells this led to a significant reduction of CTD phosphorylation activity of the CDK activating kinase by irradiation of the cells. On the other hand in
p53
cells no downregulation of CTD phosphorylation activity of CAK kinase was observed indicating that this kind of negative regulation of CAK kinase activity is exclusively due to a functional
p53
. These findings imply a direct involvement of
p53
in triggering growth arrest by its interaction with the CDK activating kinase complex without the need of cyclin-dependent kinase inhibitors (CKIs) and potentially suggest a new mechanism for
p53
-dependent apoptosis.
...
PMID:Regulation of CAK kinase activity by p53. 984 Sep 37
The
p53 tumor suppressor protein
, found mutated in over 50% of all human tumors, is a sequence-specific
transcriptional activator
. Recent studies have identified a
p53
relative, termed p73. We were interested in determining the relative abilities of wild-type and mutant forms of
p53
and p73alpha and -beta isoforms to transactivate various
p53
-responsive promoters. We show that both p73alpha and p73beta activate the transcription of reporters containing a number of
p53
-responsive promoters in the
p53
-null cell line H1299. However, a number of significant differences were observed between
p53
and p73 and even between p73alpha and p73beta. Additionally, a Saccharomyces cerevisiae-based reporter assay revealed a broad array of transcriptional transactivation abilities by both p73 isoforms at 37 degreesC. Recent data have shown that p73 can associate with
p53
by the yeast two-hybrid assay. When we examined complex formation in transfected mammalian cells, we found that p73alpha coprecipitates with mutant but not wild-type
p53
. Since many tumor-derived
p53
mutants are capable of inhibiting transactivation by wild-type
p53
, we tested the effects of two representative hot-spot mutants (R175H and R248W) on p73. By cotransfecting p73alpha along with either
p53
mutant and a
p53
-responsive reporter, we found that both R175H and R248W reduces the transcriptional activity of p73alpha. This decrease in transcriptional activity is correlated with the reduced ability of p73alpha to promote apoptosis in the presence of tumor-derived
p53
mutants. Our data suggest the possibility that in some tumor cells, an outcome of the expression of mutant p53 protein may be to interfere with the endogenous p73 protein.
...
PMID:p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. 989 Oct 77
The tumor suppressor gene
p53
is a major player in the protection of cells from DNA damage. In the majority of human cancers,
p53
is functionally inactivated--mostly by mutations but also by interaction with viral or cellular proteins. Wild-type
p53
is involved in essential functions such as DNA repair, transcription, genomic stability, senescence, cell cycle control and apoptosis. It was shown to be a sequence-specific
transcriptional activator
, and this activity appears to be necessary to impose growth arrest. A major target gene which participates in
p53
-mediated growth arrest is p21/Waf1, an inhibitor of cyclin-dependent kinases. Whether or not transcriptional activation of target genes is required for
p53
-mediated apoptosis may depend on the cell type and external factors, and the mechanism of cell death induction is not clear yet. We have employed clones of the M1 myeloid leukemic cell line expressing a temperature-sensitive
p53
mutant to study genes which are regulated during
p53
-induced apoptosis.
...
PMID:Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death. 1002 1
The
p53
tumour suppressor protein is a
transcriptional activator
, which can induce cell cycle arrest and apoptosis.
p53
Gene mutations occur in more than 50% of all human tumours. Reintroduction of wild-type
p53
but also of oligomerisation-independent
p53
variants into tumour cells by gene transfer methods has been considered. We have investigated the biological properties of two carboxy-terminal deletion mutants of
p53
,
p53
delta 300 (comprising amino acids 1-300) and
p53
delta 326 (amino acids 1-326), to evaluate their potential deployment in gene therapy. Transactivation was measured in transiently transfected HeLa and SKBR3 cells. Both monomeric variants showed reduced activities compared with wild-type
p53
. Individual promoters were differently affected. In contrast to wild-type
p53
, monomeric variants were not able to induce apoptosis. We also provided wild-type
p53
and
p53
delta 326 with tetracycline-regulated promoters and stably introduced these constructs into Saos2 and SKBR3 cells. Upon induction, wild-type
p53
expressing cells, but not
p53
delta 326 expressing cells underwent apoptosis. Consistently, only wild-type
p53
expressing cells accumulated p21/waf1/cip1 mRNA and protein and showed increased bax, Gadd45 and mdm2 mRNA. Neither wild-type
p53
nor
p53
delta 326 repressed the transcription of the IGF-1R gene in these cell lines. We conclude that the transactivation potential of monomeric, carboxy-terminally truncated p53 is not sufficient to cause induction of the endogenous target genes which trigger apoptosis.
...
PMID:Transcriptional regulation and induction of apoptosis: implications for the use of monomeric p53 variants in gene therapy. 1002 42
The
p53 tumor suppressor
gene is mutated in over 50% of human cancers, resulting in inactivation of the wild-type (wt)
p53 protein
. The most notable biochemical feature of
p53
is its ability to act as a sequence-specific
transcriptional activator
. Through use of the suppression subtractive hybridization differential screening technique, we identified c-fos as a target for transcriptional stimulation by
p53
in cells undergoing
p53
-mediated apoptosis. Overexpression of wt
p53
induces c-fos mRNA and protein. Moreover, in vivo induction of c-fos in the thymus following whole-body exposure to ionizing radiation is
p53
dependent.
p53
responsiveness does not reside in the basal c-fos promoter. Rather, a distinct region within the c-fos gene first intron binds specifically to
p53
and confers upon the c-fos promoter the ability to become transcriptionally activated by wt
p53
. Identification of c-fos as a specific target for transcriptional activation by
p53
establishes a direct link between these two pivotal regulatory proteins and raises the possibility that c-fos contributes to some of the biological effects of
p53
.
...
PMID:The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. 1008 25
The
p53 tumor suppressor
gene, which is considered the guardian of the genome, encodes a phosphoprotein, which is a sequence-specific
transcriptional activator
or repressor of target genes. The role of
p53
in developmental processes has not been studied extensively, although its expression appears to undergo temporal and spatial changes during prenatal and postnatal development. In the present study, we assessed the levels of
p53 mRNA
and protein in the developing rat brain and its relation to developmental cell death. Furthermore, we investigated the potential role of n-methyl-d-aspartate (NMDA) receptors in regulating
p53
expression, since these receptors are involved in the control of cell death. We found that
p53 mRNA
and protein were detectable in the rat brain throughout perinatal development. In embryos,
p53
immunoreactivity was mainly localized in the nuclei of neuroepithelial cells, with a maximum in staining at embryonic day (E)12. In the neuroepithelium, we also found significant numbers of TdT-mediated dUTP nick end labeling (TUNEL)-positive cells, both in dividing periventricular cells and in migrating neurons. In neonates, immediately after birth there was a reduction in the number of apoptotic cells, which then increased to reach a maximum at postnatal day (P)5. Postnatally, apoptotic as well as
p53
-positive cells were detected in most brain areas.
P53
immunoreactivity was also highest on P5. In most cells,
p53
immunoreactivity and the TUNEL signal colocalized.
P53
immunoreactivity as well as the number of TUNEL- positive cells were dramatically decreased in the brains of newborns treated with MK-801, an NMDA receptor antagonist. Our results show that
p53
is involved in the control of developmental cell death, and that NMDA receptors play a regulatory role in the expression of the
p53
gene, and thus in apoptosis occurring in the developing rat brain.
...
PMID:p53 expression and regulation by NMDA receptors in the developing rat brain. 1034 Jul 50
The role that the
p53 tumor suppressor
gene product plays in cellular differentiation remains controversial. However, recent evidence indicates that
p53
is required for proper embryogenesis. We have studied the effect of
p53
on the expression mediated by the promoter of the rat muscle-specific phosphoglycerate mutase gene (M-PGAM), a marker for cardiac and skeletal muscle differentiation. Experiments involving transient transfection, mobility shift assay, and site-directed mutagenesis demonstrated that
p53
specifically binds and transactivates the M-PGAM promoter. The
p53
-related proteins p51A and p73L also transactivated M-PGAM. Moreover, stable expression of a
p53
dominant mutant in C2C12 cells blocked the induction of M-PGAM expression during the myoblast to myotube transition and the ability of
p53
, p51A, and p73L to transactivate the M-PGAM promoter. In addition, impaired expression of M-PGAM was observed in a subset of
p53
-null animals in heart and muscle tissues of anterior-ventral location. These results demonstrate that
p53
is a
transcriptional activator
of M-PGAM that contributes in vivo to the control of its cardiac expression. These data support previous findings indicating a role for
p53
in cellular differentiation.
...
PMID:p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression. 1035 11
p51/p63 is a novel
p53
homologue that has been shown to act as a
transcriptional activator
through the
p53
-binding sequence of the p21/WAF1 promoter and to induce apoptosis when it is expressed transiently in a human tumor cell line. We developed transcription assay systems for these two related genes in both Saccharomyces cerevisiae and mammalian cells and used them to investigate the functional similarities and differences of these genes. We found that p51/p63 trans-activated the previously identified p53 target genes, but the degree of the transactivation by p51/p63 differed from that by
p53
. These results suggest that the cellular signal on p51/p63 cross-talks partially but not completely with that of the
p53
pathway.
...
PMID:The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. 1038 30
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>